The 2026 Summit for Novel Therapeutics in Oncology and Precision Medicine in Cancer (STOP Cancer) will bring together many of the world’s leading oncology researchers, physician-scientists, and clinical innovators on August 7-8, 2026, at the New York Marriott Marquis in Times Square.

The multidisciplinary conference is designed to bridge groundbreaking translational research with real-world patient care, highlighting the latest advances in precision medicine, targeted therapies, antibody-drug conjugates (ADCs), biomarker-driven treatment strategies, immunotherapy, radiopharmaceuticals, and early-phase clinical trials. The program will feature nationally recognized experts from leading institutions including Memorial Sloan Kettering Cancer Center, Stanford Cancer Institute, Mayo Clinic, Dana-Farber Cancer Institute, Vanderbilt University Medical Center, MD Anderson Cancer Center, and NEXT Oncology.

Among the distinguished faculty is Dr. Sarat Chandarlapaty of Memorial Sloan Kettering Cancer Center, who will deliver the prestigious Daniel D. Von Hoff Keynote Lecture. Dr. Chandarlapaty is internationally recognized for his contributions to breast cancer research and precision oncology.

The summit also features an exceptional lineup of speakers who are helping define the future of cancer therapeutics, including:

• Dr. Vivek Subbiah, Stanford Cancer Institute, a globally recognized leader in drug development and precision oncology, presenting on the evolution and future of tumor-agnostic therapies.

• Dr. Eileen M. O’Reilly, Memorial Sloan Kettering Cancer Center, one of the nation’s foremost experts in gastrointestinal malignancies, discussing recent precision medicine advances in GI cancers.

• Dr. Alexander I. Spira, Chief Scientific Officer of NEXT Oncology, presenting emerging developments in RAS-targeted therapies and next-generation oncology drug development.

• Dr. Anthony W. Tolcher, Founder and CEO of NEXT Oncology and a pioneer in early-phase clinical trials, discussing innovative approaches including RAS PROTACs and molecular glues.

• Dr. Cathy Eng, Vanderbilt University Medical Center and Co-Chair of the National Cancer Institute Gastrointestinal Steering Committee, presenting on ctDNA applications and biomarker-driven management strategies in colorectal cancer.

• Dr. Vamsi Velcheti, Mayo Clinic, an internationally recognized thoracic oncologist and cancer researcher, discussing the development of antibody-drug conjugates in lung cancer.

• Dr. Guru P. Sonpavde, AdventHealth Cancer Institute, a leading investigator in genitourinary oncology and phase I clinical research, presenting on ADC innovation in GU malignancies.

• Dr. Eytan Stein, Memorial Sloan Kettering Cancer Center, one of the nation’s leading leukemia drug development experts, discussing precision medicine advances in myeloproliferative neoplasms.

• Dr. Ghassan K. Abou-Alfa, Memorial Sloan Kettering Cancer Center, a globally respected authority in hepatobiliary cancers, presenting emerging innovations in HER2-targeted therapy.

• Dr. Ulka Vaishampayan, University of Michigan Rogel Cancer Center, discussing advances in alpha-emitter radiopharmaceutical therapies for prostate cancer.

Additional presentations will explore emerging TP53-targeted therapies, PRMT5 inhibitors, novel biomarker methodologies, digital biomarkers, clinical trial innovation, patient-reported outcomes, decentralized clinical trials, and next-generation immunotherapy approaches.

“The pace of innovation in oncology has never been greater,” said Dr. Hani Babiker, Course Director and Associate Professor of Medicine at Mayo Clinic. “STOP Cancer was created to provide a forum where clinicians, researchers, and healthcare professionals can engage directly with leaders developing the therapies and technologies that will shape the future of cancer care.”

The conference is intended for medical oncologists, hematologists, radiation oncologists, surgical oncologists, advanced practice providers, pharmacists, nurses, fellows, researchers, and other healthcare professionals involved in cancer care.

Register now.